Post-exposure HIV prophylaxis

References

Key articles

Fisher M, Briggs E, Cresswell F, et al. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (PEPSE). 2015 [internet publication].Full text

Centers for Disease Control and Prevention; US Department of Health and Human Services. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV. May 2018 [internet publication].Full text

Ford N, Mayer KH; World Health Organization Postexposure Prophylaxis Guideline Development Group. World Health Organization guidelines on postexposure prophylaxis for HIV: recommendations for a public health approach. Clin Infect Dis. 2015 Jun 1;60 Suppl 3:S161-4.Full text  Abstract

Reference articles

1. Pinto LA, Landay AL, Berzofsky JA, et al. Immune response to human immunodeficiency virus (HIV) in healthcare workers occupationally exposed to HIV-contaminated blood. Am J Med. 1997 May 19;102(5B):21-4. Abstract

2. Spira AI, Marx PA, Patterson BK, et al. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med. 1996 Jan 1;183(1):215-25.Full text  Abstract

3. Fisher M, Briggs E, Cresswell F, et al. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (PEPSE). 2015 [internet publication].Full text

4. New York State Department of Health AIDS Institute. PEP for occupational exposure to HIV guideline. May 2018 [internet publication].Full text

5. New York State Department of Health AIDS Institute. PEP for non-occupational exposure to HIV guideline. May 2018 [internet publication].Full text

6. Centers for Disease Control and Prevention; US Department of Health and Human Services. Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV. May 2018 [internet publication].Full text

7. Department of Health. HIV post-exposure prophylaxis: guidance from the UK Chief Medical Officers' Expert Advisory Group on AIDS. September 2008 [internet publication].Full text

8. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. October 2016 [internet publication].Full text

9. Greenwald JL, Burstein GR, Pincus J, et al. A rapid review of rapid HIV antibody tests. Curr Infect Dis Rep. 2006 Mar;8(2):125-31. Abstract

10. Schechter M, do Lago RF, Mendelsohn AB, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):519-25. Abstract

11. Fernández-Balbuena S, Belza M, Castilla J, et al. Awareness and use of nonoccupational HIV post-exposure prophylaxis among people receiving rapid HIV testing in Spain. HIV Med. 2013 Apr;14(4):252-7. Abstract

12. Minas B, Laing S, Jordan H, et al. Improved awareness and appropriate use of non-occupational post-exposure prophylaxis (nPEP) for HIV prevention following a multi-modal communication strategy. BMC Public Health. 2012 Oct 25;12:906.Full text  Abstract

13. McCarty EJ, Quah S, Maw R, et al. Post-exposure prophylaxis following sexual exposure to HIV: a seven-year retrospective analysis in a regional centre. Int J STD AIDS. 2011 Jul;22(7):407-8. Abstract

14. Draughon JE, Sheridan DJ. Nonoccupational postexposure prophylaxis for human immunodeficiency virus in Sub-Saharan Africa: a systematic review. J Forensic Nurs. 2011 Jun;7(2):89-96. Abstract

15. Arend E, Maw A, de Swardt C, et al. South African sexual assault survivors' experiences of post-exposure prophylaxis and individualized nursing care: a qualitative study. J Assoc Nurses AIDS Care. 2013 Mar-Apr;24(2):154-65. Abstract

16. Health Protection Agency Centre for Infections, National Public Health Service for Wales, CDSC Northern Ireland. Eye of the needle: surveillance of significant occupational exposure to bloodborne viruses in healthcare workers. December 2014 [internet publication].Full text

17. World Health Organization. Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach. December 2014 [internet publication].Full text

18. Donegan E, Stuart M, Niland JC, et al. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med. 2013 Mar-Apr;24(2):154-65. Abstract

19. Mastro TD, de Vincenzi I. Probabilities of sexual HIV-1 transmission. AIDS. 1996;10 Suppl A:S75-82. Abstract

20. Royce RA, Sena A, Cates W Jr., et al. Sexual transmission of HIV. N Engl J Med. 1997 Apr 10;336(15):1072-8. Abstract

21. de Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. N Engl J Med. 1994 Aug 11;331(6):341-6.Full text  Abstract

22. Anderson RM, May RM. Epidemiological parameters of HIV transmission. Nature. 1988 Jun 9;333(6173):514-9. Abstract

23. Gray R, Wawer MJ, Brookmeyer R, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001 Apr 14;357(9263):1149-53. Abstract

24. Leynaert B, Downs AM, de Vincenzi I; European Study Group on Heterosexual Transmission of HIV. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. Am J Epidemiol. 1998 Jul 1;148(1):88-96.Full text  Abstract

25. Overbaugh J, Sagar M, Benki S, et al. Viral and host factors in HIV-1 transmission and pathogenesis. Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections, February 24-28, 2002. Seattle, Washington, DC (abstr. S23).

26. Vittinghoff E, Douglas J, Judson F, et al. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol. 1999 Aug 1;150(3):306-11.Full text  Abstract

27. Kaplan EH, Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr. 1992;5(11):1116-8. Abstract

28. Ippolito G, Puro V, De Carli G, et al. The risk of occupational human immunodeficiency virus infection in health care workers. Arch Intern Med. 1993 Jun 28;153(12):1451-8. Abstract

29. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999 Feb;75(1):3-17.Full text  Abstract

30. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol. 2000 Oct;74(20):9771-5.Full text  Abstract

31. Tsai CC, Emau P, Follis KE, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998 May;72(5):4265-73.Full text  Abstract

32. Le Grand R, Vaslin B, Larghero J, et al. Post-exposure prophylaxis with HAART could not protect macaques from inoculation with SIV/HIV chimera. AIDS. 2000 Aug 18;14(12):1864-6. Abstract

33. Cardo DM, Culver DH, Ciesielski CA, et al. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997 Nov 20;337(21):1485-90.Full text  Abstract

34. Drezett J. Post-exposure prophylaxis in raped women. In: IV International Conference on HIV Infection in Women and Children. Rio de Janeiro: Livro de Resumos. Universidade, Federal do Rio De Janeiro e Institute of Virology of Maryland; 2002.

35. Centers for Disease Control and Prevention (CDC). Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood - France, United Kingdom, and United States, January 1988-August 1994. MMWR Morb Mortal Wkly Rep. 1995 Dec 22;44(50):929-33.Full text  Abstract

36. Bell DM. Occupational risk of human immunodeficiency virus infection in health care workers: an overview. Am J Med. 1997 May 19;102(5B):9-15. Abstract

37. Ganczak M, Barss P, Ganczak M, et al. Nosocomial HIV infection: epidemiology and prevention - a global perspective. AIDS Rev. 2008 Jan-Mar;10(1):47-61. Abstract

38. Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institutes of Health, et al. Recommendations for HIV prevention with adults and adolescents with HIV in the United States, 2014. December 2014 [internet publication].Full text

39. Waldo CR, Stall RD, Coates TJ. Is offering post-exposure prevention for sexual exposures to HIV related to sexual risk behavior in gay men? AIDS. 2000 May 26;14(8):1035-9. Abstract

40. Figueroa JP, Brathwaite A, Morris J, et al. Rising HIV-1 prevalence among sexually transmitted disease clinic attenders in Jamaica: traumatic sex and genital ulcers as risk factors. J Acquir Immune Defic Syndr. 1994 Mar;7(3):310-6. Abstract

41. Landovitz RJ, Fletcher JB, Inzhakova G, et al. A novel combination HIV prevention strategy: post-exposure prophylaxis with contingency management for substance abuse treatment among methamphetamine-using men who have sex with men. AIDS Patient Care STDS. 2012 Jun;26(6):320-8. Abstract

42. Heuker J, Sonder GJ, Stolte I, et al. High HIV incidence among MSM prescribed postexposure prophylaxis, 2000-2009: indications for ongoing sexual risk behaviour. AIDS. 2012 Feb 20;26(4):505-12. Abstract

43. Llewellyn C, Abraham C, Miners A, et al. Multicentre RCT and economic evaluation of a psychological intervention together with a leaflet to reduce risk behaviour amongst men who have sex with men (MSM) prescribed post-exposure prophylaxis for HIV following sexual exposure (PEPSE): a protocol. BMC Infect Dis. 2012 Mar 22;12:70.Full text  Abstract

44. Jain S, Krakower DS, Mayer KH. The transition from postexposure prophylaxis to preexposure prophylaxis: an emerging opportunity for biobehavioral HIV prevention. Clin Infect Dis. 2015 Jun 1;60 Suppl 3:S200-4.Full text  Abstract

45. Grant RM, Smith DK. Integrating antiretroviral strategies for human immunodeficiency virus prevention: post- and pre-exposure prophylaxis and early treatment. Open Forum Infect Dis. 2015 Aug 26;2(4):ofv126.Full text  Abstract

46. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505.Full text  Abstract

47. Rodger A, et al. HIV transmission risk through condomless sex if HIV+ partner on suppressive ART: PARTNER study. In: Program and abstracts of the 21st Conference on Retroviruses and Opportunistic Infections, March 3 to 6th, 2014, Boston, U.S., abstract 153LB.

48. Monitoring the AIDS Pandemic (MAP) Network. The determinants of the HIV/AIDS epidemics in Europe. Geneva, Switzerland: Monitoring the AIDS Pandemic (MAP) Network in conjunction with the 12th World AIDS Conference; 1998.Full text

49. Merck Frosst Canada Ltd. Isentress (raltegravir) prescribing information. January 2015 [internet publication].Full text

50. ViiV Healthcare ULC. Tivicay (dolutegravir) prescribing information. February 2014 [internet publication].Full text

51. British national formulary 73. London, UK: British Medical Association and Royal Pharmaceutical Society of Great Britain. BMJ group and RPS Publishing; 2017.

52. Corey L. Wald A, Celum CL, et al. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):435-45. Abstract

53. New York State Department of Health AIDS Institute. HIV post-exposure prophylaxis for children beyond the perinatal period. June 2010 [internet publication].Full text

54. Landovitz RJ, Currier JS. Clinical practice. Postexposure prophylaxis for HIV infection. 2009 Oct 29;361(18):1768-75. Abstract

55. Mindel A, Tenant-Flowers M. ABC of AIDS: Natural history and management of early HIV infection. BMJ. 2001 May 26;322(7297):1290-3.Full text  Abstract

56. Centers for Disease Control and Prevention; US Department of Health and Human Services. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. May 2018 [internet publication].Full text

57. Department of Health Expert Advisory Group on AIDS. EAGA guidance on HIV post-exposure prophylaxis. April 2015 [internet publication].Full text

58. Ford N, Mayer KH; World Health Organization Postexposure Prophylaxis Guideline Development Group. World Health Organization guidelines on postexposure prophylaxis for HIV: recommendations for a public health approach. Clin Infect Dis. 2015 Jun 1;60 Suppl 3:S161-4.Full text  Abstract

59. U.S. Department of Health and Human Services. Statement on potential safety signal in infants born to women taking dolutegravir from the HHS antiretroviral guideline panels. May 2018 [internet publication].Full text

60. Ford N, Shubber Z, Calmy A, et al. Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review. Clin Infect Dis. 2015 Jun 1;60 Suppl 3:S170-6.Full text  Abstract

61. Mayer KH, Mimiaga MJ, Gelman M, et al. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr. 2012 Apr 1;59(4):354-9. Abstract

62. Ford N, Irvine C, Shubber Z, et al. Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis. AIDS. 2014 Nov 28;28(18):2721-7. Abstract

63. Blashill AJ, Ehlinger PP, Mayer KH, et al. Optimizing adherence to preexposure and postexposure prophylaxis: the need for an integrated biobehavioral approach. Clin Infect Dis. 2015 Jun 1;60 Suppl 3:S187-90.Full text  Abstract

64. Naftalin C, Sikka P, Hill S, et al. Kaletra-based post-exposure prophylaxis (PEP): how does it compare in clinical practice? Sex Transm Inf. 2008;84;e1(D-18).

65. osini W, Muller P, Prazuck T, et al. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation. AIDS. 2010 Sep 24;24(15):2375-80. Abstract

66. Wood BR. Nonoccupational postexposure prophylaxis (nPEP) visits: opportunities beyond HIV PEP. Int J Infect Dis. 2015 Nov;40:131-2.Full text  Abstract

Use of this content is subject to our disclaimer